Gilead Sciences has a report that the Trump administration can reduce funds to prevent HIV

• Federal funding to prevent HIV can be reduced, according to the Wall Street Journal.

• Gilead Sciences decreased by 2.52 % in pre -market trading on news.

• The company makes medicines to treat HIV and AIDS. Other vital pharmaceutical companies also fell.

Step: Gilead Sciences decreased by 2.52 % in pre -market trading, as it decreased to $ 107.45 per share on Wednesday morning. The biological pharmaceutical company has increased by 19.34 % for this year.

Why: The arrow’s decline follows a report from Wall Street Magazine The US Department of Health and Humanitarian Services is studying radical discounts for federal financing to prevent HIV in the United States. Gilead makes treatments for adults with HIV.

The sources told the magazine that the discounts in financing are part of a wider inclined police that can be announced soon for the centers of control and prevention control, as the Trump administration is looking to reorganize the agency.

What does it mean: Reducing the HIV budget at the Center for Disease Control has effects on drug makers that focus on combating this disease. Regardless of Gilead, American GSK shares in GSK decreased by 2.18 % in early trading. A multinational biomedic company is the major owner of the VIIV company that focuses on HIV.

Read the original article on Business Insider